Molecular basis for passive immunotherapy of Alzheimer's disease
Gardberg, A.S., Dice, L.T., Ou, S., Rich, R.L., Helmbrecht, E., Ko, J., Wetzel, R., Myszka, D.G., Patterson, P.H., Dealwis, C.(2007) Proc Natl Acad Sci U S A 104: 15659-15664
- PubMed: 17895381 
- DOI: 10.1073/pnas.0705888104
- Primary Citation of Related Structures:  
2IPT, 2IPU, 2IQ9, 2IQA, 2R0W, 2R0Z - PubMed Abstract: 
Amyloid aggregates of the amyloid-beta (Abeta) peptide are implicated in the pathology of Alzheimer's disease. Anti-Abeta monoclonal antibodies (mAbs) have been shown to reduce amyloid plaques in vitro and in animal studies. Consequently, passive immunization is being considered for treating Alzheimer's, and anti-Abeta mAbs are now in phase II trials ...